Updates and news related to prostate cancer:
Expert Compares PSMA Imaging Agents, Discusses PSMA vs Axumin in Prostate Cancer
Steven Rowe, MD, PhD, provides some of the background on the PSMA-PET imaging revolution in prostate cancer and offered his insight.
Blood Tests Predict Which Prostate Cancer Patients Are Resistant to Chemotherapy Drug
The findings could enable doctors to detect early on, without invasive procedures, if a treatment is working and switch to alternatives such as abiraterone or cabazitaxel if it is not.
Proteins May Predict Lethal Prostate Cancer in African-American Patients
The proteins were only predictive for African-American patients, not European-American patients.
MRI Results Might Permit Sparing of the Transitional Zone During Prostate Biopsy
Omission of transitional-zone sampling during the systematic portion of combined biopsy reliably detected clinically significant prostate cancer.
Prostate Cancer Observation Varies With MRI, Genomic Testing Availability
Prostate MRI and genomic testing may improve the precision of management and support observation of prostate cancer.
Biomarker Testing Protocols for Metastatic Prostate Cancer
Dr. Alicia Morgans discusses biomarker testing protocols and signs to look for during testing.
Docs Disagree With Update to NCCN Guidelines for Prostate Cancer
An update to active surveillance recommendations has some physicians concerned.
Diet-Associated Molecules in the Gut are Linked with Aggressive Prostate Cancer
Findings suggest dietary interventions may help reduce risk and were published in Cancer Epidemiology, Biomarkers & Prevention.
Total Androgen Suppression Does Not Improve Overall Survival for Certain Patients With Prostate Cancer
Study does not show clinically significant improvements in overall survival but does show benefits in secondary endpoints, which included rates of distant metastases, deaths due to prostate cancer, and PSA failure.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Abiraterone plus prednisolone added to ADT significantly decreases the risk for metastasis and death compared with ADT alone in patients with high-risk nonmetastatic prostate cancer, new findings suggest.